Intellia Therapeutics, Inc. (NTLA): R&D Expense
$388.86M
Year ended 2025-12-31
$346.73M
Trailing 12 months to 2026-06-30
-2.5%
3-year compound annual growth
+20.9%
5-year compound annual growth
+42.6%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $388.86M | -16.6% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $466.31M | +7.2% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $435.07M | +3.6% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $419.98M | +82.8% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $229.81M | +52.8% | 2024-02-22, From 2021-01-01 |
| 2020-12-31 | $150.41M | +38.7% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $108.41M | +21.7% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $89.11M | +31.7% | 2021-02-26, From 2018-01-01 |
| 2017-12-31 | $67.65M | +112.5% | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | $31.84M | +185.0% | 2019-02-27, From 2016-01-01 |
| 2015-12-31 | $11.17M | n/a | 2018-03-14, From 2015-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | $388.86M | -16.6% |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $2.20M | -20.4% |
| Immucell Corp (ICCC) | 2025-12-31 | $3.04M | -22.0% |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | $2.88M | -11.9% |
| Anbio Biotechnology (NNNN) | 2025-12-31 | $201.3K | -55.7% |
| Myriad Genetics Inc (MYGN) | 2025-12-31 | $106.80M | -5.8% |
| Neogen Corp (NEOG) | 2026-05-31 | $18.40M | -12.8% |
| Biomerica Inc (BMRA) | 2026-05-31 | $788.0K | -23.0% |
| Insight Molecular Diagnostics Inc. (IMDX) | 2025-12-31 | $15.90M | +61.6% |
Compare NTLA, TKNO, ICCC, AWHL side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗